ESX1 Antibody is affinity chromatography purified via peptide column.
Immunogen
ESX1 antibody was raised against a 19 amino acid synthetic peptide near the center of human ESX1. The immunogen is located within amino acids 140 - 190 of ESX1.
ESX1
Reaktivität: Human
WB, ELISA
Wirt: Kaninchen
Polyclonal
APC
Applikationshinweise
ESX1 antibody can be used for detection of ESX1 by Western blot at 1 - 2 μ,g/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μ,g/mL. For immunofluorescence start at 20 μ,g/mL.
Antibody validated: Western Blot in human samples, Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
ESX1 Antibody is supplied in PBS containing 0.02 % sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C,4 °C
Informationen zur Lagerung
ESX1 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
ESX1 Antibody: Homeobox proteins are transcription factors that contain a helix-turn-helix DNA binding domain termed the homeodomain. ESX1 is an X-linked homeobox gene primarily expressed in the placenta and testis and contains two functional domains: the homeodomain and the proline-rich domain. During embryogenesis, ESX1 is expressed in the extraembryonic tissues, including the endoderm of the visceral yolk sac, the ectoderm of the chorion and the labyrinthine trophoblast of the chorioallantoic placenta. ESX1 can act like a transcriptional repressor to the human oncogene K-ras and treatment of human cancer cells with an ESX1 protein fragment containing the homeodomain reduces the tumorgenicity of cells containing oncogenic K-ras mutations, suggesting ESX1 may be useful as a therapeutic treatment for these cancers.